Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Metabolic Disorders Cardiovascular Clinical Trials

Orchid invests in Diakron

This article was originally published in Scrip

  • News

Executive Summary

Orchid Chemicals and Pharmaceuticalshas acquired majority control in Diakron Pharmaceuticals, the US drug development firm that has an exclusive licence for an investigational oral anticoagulant drug candidate discovered and developed through Phase I by Merck & Co. Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Cardiovascular Clinical Trials
UsernamePublicRestriction

Register

SC005874

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By